GlassScriptPhysician profile
Sadek Debwan
NPI 1396368585
$2,479.54
in general payments reported to CMS, 2019-2025
20 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $285 · 2023: $515 · 2024: $860 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $511.72 | 2021-2025 | Botox, Ubrelvy |
| Emd Serono, INC. | $389.85 | 2023-2024 | Mavenclad |
| Biogen, INC. | $169.76 | 2022-2023 | Vumerity |
| Eisai INC. | $167.87 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $164.83 | 2024-2025 | Ingrezza |
| Boston Scientific Corporation | $162.88 | 2023 | Watchman Access System |
| Galderma Laboratories, L.P. | $150.00 | 2025 | Nemluvio |
| Otsuka America Pharmaceutical, INC. | $131.17 | 2023 | Rexulti |
| Catalyst Pharmaceuticals, INC. | $125.00 | 2022 | |
| Amgen INC. | $116.53 | 2024 | Uplizna |
| Lilly USA, LLC | $88.99 | 2024-2025 | Kisunla, Amyvid |
| Abbott Laboratories | $71.46 | 2024 | Eterna |
| Regeneron Healthcare Solutions, INC. | $70.97 | 2025 | Dupixent |
| Corium, LLC | $47.99 | 2023 | Azstarys |
| Argenx US, INC. | $24.61 | 2025 | Vyvgart Hytrulo, Vyvgart |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.65 | 2023 | Ocrevus |
| Sk Life Science, INC. | $20.04 | 2024 | |
| Avanir Pharmaceuticals, INC. | $15.72 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.32 | 2022 | |
| Neurelis, INC. | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadek Debwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.